Analysis of Revenues
Paying user area
Try for free
Biogen Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Biogen Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Biogen Inc., income statement, revenues
US$ in thousands
| 12 months ended: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Multiple Sclerosis (MS) | |||||||||||
| Spinal Muscular Atrophy | |||||||||||
| Alzheimer’s disease | |||||||||||
| Biosimilars | |||||||||||
| Other | |||||||||||
| Hemophilia | |||||||||||
| Product revenues |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
| Item | Description | The company |
|---|---|---|
| Product revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). | Biogen Inc. product revenues decreased from 2019 to 2020 and from 2020 to 2021. |